Register Login
Register to leave comments
  • News bot March 14, 2026, 1:37 a.m.

    🔍 RUBINSTEIN JULIE (Executive)

    Company: Adaptive Biotechnologies Corp (ADPT)

    Report Date: 2026-03-11

    Transaction Summary:

    • Total transactions: 11
    • Derivative instruments: 3
    • Holdings reported: 0
    • Total shares acquired: 44,166
    • Total shares sold: 223,869

    Detailed Transactions and Holdings:

    • Sold 122,523 shares of Common Stock at $13.17 per share (Direct)
      Date: 2026-03-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 520,948.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 14,722 shares of Common Stock at $6.55 per share (Direct)
      Date: 2026-03-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 535,670.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 19,060 shares of Common Stock at $14.08 per share (Direct)
      Date: 2026-03-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 516,610.00 | transaction_form_type: 4 | Footnotes: F2, F3
    • Acquired 14,722 shares of Common Stock at $6.55 per share (Direct)
      Date: 2026-03-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 531,332.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 13,660 shares of Common Stock at $12.63 per share (Direct)
      Date: 2026-03-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 517,672.00 | transaction_form_type: 4 | Footnotes: F2, F4
    • Sold 5,400 shares of Common Stock at $13.43 per share (Direct)
      Date: 2026-03-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 512,272.00 | transaction_form_type: 4 | Footnotes: F2, F5
    • Acquired 14,722 shares of Common Stock at $6.55 per share (Direct)
      Date: 2026-03-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 526,994.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 19,060 shares of Common Stock at $12.96 per share (Direct)
      Date: 2026-03-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 507,934.00 | transaction_form_type: 4 | Footnotes: F2, F6
    • Sold 14,722 shares of Stock Option (right to buy) at $6.55 per share (Derivative)
      Date: 2026-03-11 | Code: M | Expires: 2028-02-07 | equity_swap_involved: 0 | shares_owned_after: 92,271.00 | transaction_form_type: 4 | Footnotes: F2, F7
    • Sold 14,722 shares of Stock Option (right to buy) at $6.55 per share (Derivative)
      Date: 2026-03-12 | Code: M | Expires: 2028-02-07 | equity_swap_involved: 0 | shares_owned_after: 77,549.00 | transaction_form_type: 4 | Footnotes: F2, F7
    • Sold 14,722 shares of Stock Option (right to buy) at $6.55 per share (Derivative)
      Date: 2026-03-13 | Code: M | Expires: 2028-02-07 | equity_swap_involved: 0 | shares_owned_after: 62,827.00 | transaction_form_type: 4 | Footnotes: F2, F7

    Footnotes:

    • F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
    • F2: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
    • F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.83 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.11 to $13.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.12 to $13.76, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F6: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F7: The option is fully vested and exercisable.

Search

News categories